Doxorubicin activity is enhanced by hyperthermia in a model of ex vivo vascular perfusion of human colon carcinoma

World Journal of Surgery

Volumn 27, Issue 6, 2003, Pages 640-646

  Pilati, Pierluigi ^a   Mocellin, Simone ^a   Rossi, Carlo R ^a   Scalerta, Romano ^a   Alaggio, Rita ^a   Giacomelli, Luciano ^a   Geroni, Cristina ^b   Nitti, Donato ^a   Lise, Mario ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE; DOXORUBICIN; TOPOISOMERASE 2ALPHA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; COLON CARCINOMA; COLON RESECTION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG UPTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; HYPERTHERMIC THERAPY; PERFUSION; PREDICTION; PROTEIN EXPRESSION; TUMOR CELL;

EID: 0043076204     PISSN: 03642313     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00268-003-6804-3     Document Type: Article

References (31)

1. Mekhail-Ishak K, Hudson N, Tsao MS, et al. Implications for therapy of drug-metabolizing enzymes in human colon cancer. Cancer Res. 1989;49:4866-4869
2. Labianca R, Pessi MA, Zamparelli G. Treatment of colorectal cancer. Current guidelines and future prospects for drug therapy. Drugs 1997;53:593-607
3. O'Connell MJ, Moertel CG, Rubin J, et al. Lack of clinical therapeutic synergism between cyclophosphamide, Adriamycin, and cis-dichlorodiammineplatinum(lI) in metastatic human colorectal carcinoma. Cancer Treat. Rep. 1980;64:311-313
4. Staley BE, Samowitz WS, Bronstein IB, et al. Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon. Mod. Pathol. 1999;12:356-361
5. Kramer R, Weber TK, Morse B, et al. Constitutive expression of multidrug resistance in human colorectal tumours and cell lines. Br. J. Cancer 1993;67:959-968
6. Itaya M, Yoshimoto J, Kojima K, et al. Usefulness of p53 protein, Bcl-2 protein and Ki-67 as predictors of chemosensitivity of malignant tumors. Oncol. Rep. 1999;6:675-682
7. Bunz F, Hwang PM, Torrance C, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 1999;104:263-269
8. Konno H, Maruo Y, Matsuda I, et al. Intra-arterial liposomal Adriamycin for metastatic adenocarcinoma of the liver. Eur. Surg. Res. 1995;27:301-306
9. Ono A, Horikoshi I, Ueno M. Study on hepatic artery chemoembolization using temperature-sensitive liposome or lipiodol emulsion. Biol. Pharm. Bull. 1995;18:279-283
10. Cay O, Kruskal JB, Nasser I, et al. Liver metastases from colorectal cancer: drug delivery with liposome-encapsulated doxorubicin. Radiology 1997;205:95-101
11. Kitazono M, Okumura H, Ikeda R, et al. Reversal of LRP-associated drug resistance in colon carcinoma SW-620 cells. Int. J. Cancer 2001;91:126-131
12. Newman MJ, Rodarte JC, Benbatoul KD, et al. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res. 2000;60:2964-2972
13. Herman TS. Temperature dependence of Adriamycin, cis-diamminedichloroplatinum, bleomycin, and 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity in vitro. Cancer Res. 1983;43:517-520
14. Goss P, Parsons PG. The effect of hyperthermia and melphalan on survival of human fibroblast strains and melanoma cell lines. Cancer Res. 1977;37:152-156
15. Creech O, Krementz E, Ryan R. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann. Surg. 1958;148:616-632
16. Alexander HR, Libutti SK, Bartlett DL, et al. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin. Cancer Res. 2000;6:3062-3070
17. Baba H, Maehara Y, Takeuchi H, et al. Optimal scheduling increases therapeutic gain of Adriamycin combined with hyperthermia. Anticancer Res. 1993;13:651-654
18. Rossi CR, Foletto M, Di Filippo F, et al. Soft tissue limb sarcomas: Italian clinical trials with hyperthermic antiblastic perfusion. Cancer 1999:86:1742-1749
19. Stein U, Jurchott K, Walther W, et al. Hyperthermia-induced nuclear translocation of transcription factor YB-1 leads to enhanced expression of multidrug resistance-related ABC transporters. J. Biol. Chem. 2001;21:21
20. Pilati PL, Rossi CR, Mocellin S, et al. Isolated vascular perfusion of human colon with adenocarcinoma. World J. Surg. 1999;23:197-201
21. Tewey KM, Rowe TC, Yang L, et al. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984;226:466-468
22. Sears HF, Herlyn D, Herlyn M, et al. Exvivo perfusion of human colon with monoclonal anticolorectal cancer antibodies. Cancer 1982;49:1231-1235
23. Murdter TE, Sperker B, Kivisto KT, et al. Enhanced uptake of doxorubicin into bronchial carcinoma: beta- glucuronidase mediates release of doxorubicin from a glucuronide prodrug (HMR 1826) at the tumor site. Cancer Res. 1997;57:2440-2445
24. Pilati P, Rossi CR, Mocellin S, et al. Multimodal treatment of peritoneal carcinomatosis and sarcomatosis. Eur. J. Surg. Oncol. 2001;27:125-134
25. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin. Biochem. Pharmacol. 1999;57:727-741
26. Heck MM, Earnshaw WC. Topoisomerase II: a specific marker for cell proliferation. J. Cell Biol. 1986;103:2569-2581
27. Heck MM, Hittelman WN, Earnshaw WC. Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc. Natl. Acad. Sci. U. S. A. 1988;85:1086-1090
28. Rice GC, Hahn GM. Modulation of Adriamycin transport by hyperthermia as measured by fluorescence-activated cell sorting. Cancer Chemother. Pharmacol. 1987;20:183-187
29. Nagaoka S, Kawasaki S, Sasaki K, et al. Intracellular uptake, retention and cytotoxic effect of Adriamycin combined with hyperthermia in vitro. Jpn. J. Cancer Res. 1986;77:205-211
30. Lynch BJ, Guinee DG, Holden JA. Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer. Hum. Pathol. 1997;28:1180-1188
31. Guinee DG, Holden JA, Benfield JR, et al. Comparison of DNA topoisomerase II alpha expression in small cell and nonsmall cell carcinoma of the lung. In search of a mechanism of chemotherapeutic response. Cancer 1996;78:729-735